The landscape of advanced therapeutics manufacturing received a significant boost as Made Scientific officially acquired an expansive 85,000-square-foot cell therapy…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
New York City-based biotechnology firm Definium Therapeutics has reached a pivotal juncture in the development of its flagship psychedelic candidate,…
Read More
Researchers Uncover Promising Dual-Drug Therapy to Overcome Differentiation Blockade in Aggressive Acute Myelogenous Leukemia
Acute myelogenous leukemia (AML) remains one of the most formidable hematological malignancies in modern oncology. Despite incremental advances in supportive…
Read More
FDA Approves Ultragenyx Gene Therapy Fayuvi for Sanfilippo Syndrome Type A at a Record-Breaking $3.95m Price Tag
In a landmark decision for pediatric neurology and rare disease research, the US Food and Drug Administration (FDA) has granted…
Read More
Cellares and GenomeFrontier Therapeutics Partner to Automate Virus-Free CAR-T Cell Therapy Manufacturing on the Cell Shuttle Platform
The global cell therapy landscape is undergoing a profound structural shift as biotechnology innovators increasingly look toward end-to-end automation to…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
The pharmaceutical landscape for psychiatric care is currently witnessing a paradigm shift as New York City-based Definium Therapeutics advances its…
Read More
Breakthrough Combination Therapy Offers New Hope for Acute Myelogenous Leukemia Patients by Targeting Cellular Differentiation Blocks
Acute myelogenous leukemia (AML) remains one of the most formidable challenges in modern oncology. Characterized by its aggressive nature and…
Read More
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Solstice Oncology has successfully closed a landmark $225 million Series A funding round to accelerate the clinical development of its…
Read More
Exegenesis Bio and Modalis Therapeutics Join Forces in Strategic Licensing Agreement to Advance MDL-201 Gene Therapy for Duchenne Muscular Dystrophy
In a significant development for the field of genetic medicine, biotechnology innovators Exegenesis Bio and Modalis Therapeutics have formally announced…
Read More
Breakthrough Micro-Bladder Model Reveals Why UTIs Keep Returning and Points to Phage Therapy as a New Defense
Urinary tract infections (UTIs) are among the most common bacterial ailments treated in clinical practice globally, yet their frustrating tendency…
Read More
